The update from previous formulas (like the XBB.1.5 and initial JN.1 versions) to the KP.2-specific LP8.1 formula is a direct scientific response to viral evolution:

• Superior Match to Circulating Virus: By late 2024, variants derived from the JN.1 lineage, primarily KP.2 and KP.3, made up the vast majority of global COVID-19 cases. Vaccines designed to match the spike protein of these dominant strains are scientifically proven to stimulate a more effective immune defense.

• Countering Immune Escape: The KP.2 variant possesses specific mutations that allow it to partially evade antibodies generated by older vaccine formulas. The LP8.1 update is engineered to "re-train" the immune system to recognise and neutralise these newer variants more effectively, restoring a higher level of protection against infection and severe disease.

• Authoritative Recommendation: This update was formally recommended by global bodies, including the World Health Organisation (WHO), and mandated by regulators like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the 2024-2025 season to ensure optimal public health protection.

Health authorities globally recommend the updated 2024-2026 COVID-19 vaccine for broad population protection. While you should always follow local official guidance, general recommendations include:

• All adults and adolescents (typically aged 12 and older).

• Individuals at higher risk of severe illness, including:

  • Adults aged 65 and older.

  • People of any age with chronic underlying health conditions (e.g., diabetes, heart or lung disease).

  • Individuals who are immunocompromised.

  • Pregnant individuals.

• For most people, a single dose of the updated vaccine is recommended if it has been at least 2-3 months since their last COVID-19 infection or vaccination.

The LP8.1-based vaccines are authorized, approved, and currently being administered in multiple regions.

• United States & Canada: The FDA authorized and Health Canada approved the KP.2-targeted Moderna and Pfizer-BioNTech vaccines in October 2024. They have been available for the 2024-2025 season since then.

• European Union: The European Commission granted marketing authorization for Comirnaty Omicron JN.1 (KP.2) and Spikevax's equivalent in late 2024.

• United Kingdom, Australia, and Other Regions: National regulators have similarly approved and are offering these updated KP.2 vaccines.

• Hong Kong: Following the global standard, the Hong Kong SAR Government has incorporated the JN.1-lineage vaccines into its vaccination program. Marina Medical provides the Comirnaty® Omicron JN.1 (KP.2) vaccine and Moderna (Spikevax) LP.8.1  to eligible individuals. For enquiries or to arrange a vaccination, please contact our clinic directly.

1. European Medicines Agency (EMA): "EMA recommends approval of Comirnaty Omicron JN.1 (KP.2)" (Press Release, November 2024).

2. U.S. Food and Drug Administration (FDA): "FDA Authorizes Updated COVID-19 Vaccines for 2024-2025 Season" (News Release, October 2024).

3. Moderna, Inc.: "Moderna Announces FDA Authorization of Updated Spikevax for 2024-2025 Season" (Press Release, October 2024).

4. Government of Hong Kong, Centre for Health Protection: "Latest Arrangements of COVID-19 Vaccination Programme" (Official Web Page, regularly updated).